An example of the latter is acquisition of EGFRT790M or EGFRC797S mutations in non small cell lung cancers upon treatment with the EGFR tyrosine kinase inhibitor erlotinib5,6. This evidence concerns the gene EGFR and non-small cell lung carcinoma.